Connection

Michael Zile to Echocardiography

Back to Details
This is a "connection" page, showing publications Michael Zile has written about Echocardiography.
Michael Zile
Connection Strength
2.134
Echocardiography
  1. Should We Test for Diastolic Dysfunction? How and How Often? JACC Cardiovasc Imaging. 2020 01; 13(1 Pt 2):297-309.
    View in: PubMed
    Score: 0.513
  2. Echocardiographic Features of Patients?With Heart?Failure and Preserved?Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 12 10; 74(23):2858-2873.
    View in: PubMed
    Score: 0.133
  3. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017 Feb 21; 135(8):724-735.
    View in: PubMed
    Score: 0.108
  4. A novel ultrasound predictor of pulmonary capillary wedge pressure assessed by the combination of left atrial volume and function: A speckle tracking echocardiography study. J Cardiol. 2015 Sep; 66(3):253-62.
    View in: PubMed
    Score: 0.094
  5. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail. 2014 Apr; 2(2):123-30.
    View in: PubMed
    Score: 0.089
  6. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail. 2014 Mar 01; 7(2):340-50.
    View in: PubMed
    Score: 0.088
  7. Left ventricular volume determined echocardiographically by assuming a constant left ventricular epicardial long-axis/short-axis dimension ratio throughout the cardiac cycle. J Am Coll Cardiol. 1992 Oct; 20(4):986-93.
    View in: PubMed
    Score: 0.081
  8. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.077
  9. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011 Dec 06; 124(23):2491-501.
    View in: PubMed
    Score: 0.076
  10. Abnormal calcium homeostasis: one mechanism in diastolic heart failure. J Am Coll Cardiol. 2011 Jul 05; 58(2):155-7.
    View in: PubMed
    Score: 0.074
  11. Patterns of structural and functional remodeling of the left ventricle in chronic heart failure. Am J Cardiol. 2008 Aug 15; 102(4):459-62.
    View in: PubMed
    Score: 0.060
  12. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
    View in: PubMed
    Score: 0.057
  13. Chronic mitral regurgitation: predictive value of preoperative echocardiographic indexes of left ventricular function and wall stress. J Am Coll Cardiol. 1984 Feb; 3(2 Pt 1):235-42.
    View in: PubMed
    Score: 0.044
  14. Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg. 2002 Apr; 123(4):707-14.
    View in: PubMed
    Score: 0.039
  15. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 08 03; 10(15):e019545.
    View in: PubMed
    Score: 0.037
  16. Reply: Different Phenotype Characterization in PARAGON-HF: An Unresolved Puzzle in Patients With HFpEF. J Am Coll Cardiol. 2020 03 31; 75(12):1501-1502.
    View in: PubMed
    Score: 0.034
  17. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). Am Heart J. 2020 04; 222:183-190.
    View in: PubMed
    Score: 0.033
  18. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. J Am Heart Assoc. 2019 09 03; 8(17):e013114.
    View in: PubMed
    Score: 0.033
  19. Age-Related Characteristics and Outcomes of Patients With Heart?Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 08 06; 74(5):601-612.
    View in: PubMed
    Score: 0.032
  20. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018 12 11; 138(24):2763-2773.
    View in: PubMed
    Score: 0.031
  21. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019 01; 21(1):23-36.
    View in: PubMed
    Score: 0.030
  22. Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. Am Heart J. 2018 11; 205:1-11.
    View in: PubMed
    Score: 0.030
  23. Left ventricular layer function in hypertension assessed by myocardial strain rate using novel one-beat real-time three-dimensional speckle tracking echocardiography with high volume rates. Hypertens Res. 2015 Aug; 38(8):551-9.
    View in: PubMed
    Score: 0.024
  24. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 Oct; 16(10):1096-103.
    View in: PubMed
    Score: 0.023
  25. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014 Dec 21; 35(48):3442-51.
    View in: PubMed
    Score: 0.023
  26. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014 Apr; 2(2):97-112.
    View in: PubMed
    Score: 0.022
  27. Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. Am J Hypertens. 2013 Oct; 26(10):1234-41.
    View in: PubMed
    Score: 0.021
  28. Changes in diastolic function during development and correction of chronic LV volume overload produced by mitral regurgitation. Circulation. 1993 Apr; 87(4):1378-88.
    View in: PubMed
    Score: 0.021
  29. Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance. Circulation. 1992 Dec; 86(6):1718-26.
    View in: PubMed
    Score: 0.020
  30. Effect of chronic supraventricular tachycardia on left ventricular function and structure in newborn pigs. J Am Coll Cardiol. 1992 Dec; 20(7):1650-60.
    View in: PubMed
    Score: 0.020
  31. Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. J Card Fail. 2012 Jun; 18(6):487-92.
    View in: PubMed
    Score: 0.020
  32. The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens. 2011 Sep; 29(9):1829-36.
    View in: PubMed
    Score: 0.019
  33. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. Circulation. 1991 Feb; 83(2):635-44.
    View in: PubMed
    Score: 0.018
  34. Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. Am J Cardiol. 2011 Jan 15; 107(2):321-4.
    View in: PubMed
    Score: 0.018
  35. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007 Jun 23; 369(9579):2079-87.
    View in: PubMed
    Score: 0.014
  36. Myocardial mechanisms causing heart failure early after cardiac transplantation. Transplant Proc. 2006 Nov; 38(9):2999-3003.
    View in: PubMed
    Score: 0.013
  37. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J Thromb Thrombolysis. 2005 Dec; 20(3):147-53.
    View in: PubMed
    Score: 0.013
  38. Left ventricular stress-dimension-shortening relations before and after correction of chronic aortic and mitral regurgitation. Am J Cardiol. 1985 Jul 01; 56(1):99-105.
    View in: PubMed
    Score: 0.012
  39. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005 Apr; 11(3):191-5.
    View in: PubMed
    Score: 0.012
  40. Evaluation of myocardial function in cardiomyopathic states. Prog Cardiovasc Dis. 1984 Sep-Oct; 27(2):115-32.
    View in: PubMed
    Score: 0.012
  41. Coronary blood flow after the regression of pressure-overload left ventricular hypertrophy. Circ Res. 1992 Dec; 71(6):1472-81.
    View in: PubMed
    Score: 0.005
  42. Dialysis-induced alterations in left ventricular filling: mechanisms and clinical significance. Am J Kidney Dis. 1991 Mar; 17(3):277-85.
    View in: PubMed
    Score: 0.005
  43. Stress-shortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation. 1989 Apr; 79(4):872-83.
    View in: PubMed
    Score: 0.004
  44. Serial changes in left ventricular function after correction of chronic aortic regurgitation. Dependence on early changes in preload and subsequent regression of hypertrophy. Am J Cardiol. 1983 Feb; 51(3):476-82.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.